Zevra Therapeutics, Inc. (ZVRA) Operating income 2016–2025
Zevra Therapeutics, Inc. (ZVRA) annual operating income history from SEC filings — each fiscal year as reported.
-$62.9MFY2025 · since FY2016: -$37.5M → -$62.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$62.9M | +27.7% |
| FY2024 | -$87.0M | -75.4% |
| FY2023 | -$49.6M | -16.5% |
| FY2022 | -$42.6M | -650.7% |
| FY2021 | $7.7M | +237.8% |
| FY2020 | -$5.6M | +72.4% |
| FY2019 | -$20.3M | +63.6% |
| FY2018 | -$55.9M | -67.5% |
| FY2017 | -$33.4M | +11.0% |
| FY2016 | -$37.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ZVRA financial trends
ZVRA RevenueZVRA Net incomeZVRA Net marginZVRA Gross profitZVRA Gross marginZVRA Operating marginZVRA Operating cash flowZVRA Free cash flowZVRA Capital expendituresZVRA Return on equityZVRA Stock buybacksZVRA Dividends paidZVRA Total assetsZVRA Total liabilitiesZVRA Shareholders’ equityZVRA overview →